Business
NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
- NRx has Validated a Formulation, Manufacture, and Container Closure Method Suitable for High Volume Manufacture with Anticipated 1 year or greater stability
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"- NRx has Validated a Formulation, Manufacture, and Container Closure Method Suitable for High Volume Manufacture with Anticipated 1 year or greater stability\n - New Manufacturing Method Designed According to Good Manufacturing Practices (GMP) Regulations as Implemented by US Food and Drug Administration, European Medicines Agency, and Other Regulatory Authorities\n - New Formulation to be Implemented in Ongoing National Institutes of Health and I-SPY Clinical Trials and Emergency Use Programs as Allowed by Regional Authorities\n\n\nRADNOR, Pa., July 22, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has validated the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under appropriate storage conditions. Simultaneously, NRx has achieved a 30-to-50-fold increase in its manufactured lot size of aviptadil, with a concurrent 90% reduction in the cost of its peptide supply. These two developments position NRx to potentially deliver millions of doses of ZYESAMI™ as potential regulatory approvals are obtained in various regions worldwide.\n\n \n \n \n \n \n \n\n \nNRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™\"When we began developing aviptadil for treatment of COVID-19, we discovered that the original RLF-100 formulation and manufacturing method had only a few weeks of stability, leaving hospitals unable to stock the investigational medicine in pharmacies, and leaving aviptadil out of consideration for national strategic stockpiles. Moreover, the high cost of peptide and an inability to manufacture more than 100 grams a month limited the commercial utility of aviptadil,\" said Prof Jonathan Javitt, MD, MPH, Chairman and CEO of NRx. \"We have now turned the corner and can produce both the aviptadil peptide and finished medicine in million dose quantities. We have also developed and validated the first modern chromatography assays required to ensure the purity and stability of the drug product. The new formulation method and high-speed manufacturing process adapts to the fragile nature of vasoactive intestinal peptide.\"\nAs the Delta variant and more threatening, newer mutations of the Coronavirus continue to erode the immunity created by first-generatio...